Here is the rundown on market activity for Opko Health, Inc. (NASDAQ:OPK). Phillip Md Et Al Frost, CEO disclosed the purchase of 25,000 shares of (OPK). The shares were bought on June 9th for an average price of $6.38. The CEO now owns $1,041,114,832 of the stock according to the SEC filing. Phillip Md Et Al Frost, CEO bought $349,168 worth of shares at an average price of $6.28 on Wed the 7th. Frost now owns $1,024,639,418 of stock per an SEC filing yesterday.
Phillip Md Et Al Frost, CEO disclosed the purchase of 30,000 shares of OPK stock. The shares were purchased at an average price of $6.31. Frost now owns $1,029,183,356 of the stock per the Form 4 SEC filing.
OPKO Health, Inc., launched on November 18, 1991, is a diversified healthcare company. The Business’s segments include Pharmaceutical, Diagnostics and Corporate. The pharmaceutical segment consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. The diagnostics segment primarily consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations..
The following firms have also recently changed their position in OPK. As of quarter end Mivtachim The Workers Social Insurance Fund Ltd. (under Special Management) had bought 1,161,086 shares growing its holdings by 59.6%. The value of the investment in (OPK) increased from $18,115,000 to $24,872,000 increasing 37.3% quarter over quarter. As of the end of the quarter Piedmont Investment Advisors LLC had acquired a total of 102,063 shares growing its stake by 173.7%. The value in dollars went from $546,000 to $1,287,000 a change of 135.7% since the last quarter.
As of the end of the quarter Proficio Capital Partners LLC had sold 524 shares trimming its position 84.8%. The value in dollars decreased from $6,000 to $1,000 decreasing 83.3% quarter over quarter. Morgan Stanley added to its ownership by buying 2,600 shares an increase of 2.5%. Morgan Stanley currently owns 107,182 shares worth $857,000. The value of the position overall is down by 11.9%.
On June 3 analysts at Standpoint Research initiated coverage by announcing an initial rating of “Buy”. On March 31 Barrington Research made no change to the stock rating of “Outperform” and moved down the price target to $16.00 from $17.00.
Equity analyst JP Morgan starting coverage on OPK with an initial rating of “Overweight” and projecting a price target of $14.00. Laidlaw & Co started covering OPK giving it an initial rating of “Buy” and establishing a price target of $22.00.
On March 26, 2015 Barrington Research began coverage setting a rating of “Outperform” and setting a price target of $19.00. On March 3 the company was rated “Perform” by Oppenheimer down from the previous “Outperform” rating.
In the market the company is trading up by 1.92% since yesterday’s close of $6.26. The stock last traded at $6.38 slightly below $6.93, the 50 day moving average and a bit lower than the 200 day moving average of $8.49. The 50 day moving average was down $-0.55 and the 200 day average went down by -24.87%.
As of the latest earnings report the EPS was $-0.08 and is expected to be $-0.20 for the current year with 559,388,000 shares outstanding. Analysts expect next quarter’s EPS to be $-0.05 and the next full year EPS is projected to be $-0.03.
Investors are more bullish on shares of Opko Health, Inc. recently as implied by the motion in short interest. The firm saw a fall in short interest from May 15, 2017 to April 28, 2017 of -0.59%. Short shares decreased from 74,484,731 to 74,047,458 over that timeframe. With short interest at 74,047,458 and short average daily volume at 5,268,851, the short-interest ratio is 14.1 and the percentage of shorted shares is 0.13% as of April 28.